- Trials with a EudraCT protocol (116)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
116 result(s) found for: DaT scan.
Displaying page 1 of 6.
EudraCT Number: 2007-004489-41 | Sponsor Protocol Number: MRZ 90001-0716/1 | Start Date*: 2008-02-21 | |||||||||||
Sponsor Name:Merz Pharmaceuticals GmbH | |||||||||||||
Full Title: Prospective, single-arm, multi-center, open-label study to investigate the potential to reduce concomitant antipsychotics use in subjects with moderate dementia of Alzheimer’s type [DAT] treated wi... | |||||||||||||
Medical condition: Dementia of Alzheimer’s Type [DAT] in subjects with Mini Mental State Examination [MMSE] score 10-19 and Global Deterioration Scale [GDS] score 3-5 and antipsychotics medication during the last 3 m... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001100-12 | Sponsor Protocol Number: 1198.022 | Start Date*: 2004-08-09 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma Ges mbH | |||||||||||||
Full Title: A multi-centre, double-blind, parallel-group, randomised, placebo-controlled study to investigate the safety and tolerability of 0.25, 0.5 and 1.0 mg NS 2330 orally and once daily during a 14-week ... | |||||||||||||
Medical condition: Mild to moderate dementia of the Alzheimer's type | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003728-64 | Sponsor Protocol Number: E2027-G000-201 | Start Date*: 2018-12-03 | |||||||||||
Sponsor Name:Eisai Ltd | |||||||||||||
Full Title: A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies | |||||||||||||
Medical condition: Dementia With Lewy Bodies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002317-12 | Sponsor Protocol Number: ACT10019 | Start Date*: 2006-08-29 |
Sponsor Name:Sanofi-aventis | ||
Full Title: A double-blind placebo-controlled study of the activity of AVE1625 at doses of 10 mg and 40mg for 12 weeks in patients with mild to moderate Alzheimer's Disease | ||
Medical condition: Mild to moderate Alzheimer Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) SE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-003362-17 | Sponsor Protocol Number: MPC-7869-05-009.02 | Start Date*: 2008-01-04 | |||||||||||
Sponsor Name:Myriad Pharmaceuticals, Inc | |||||||||||||
Full Title: Open Label Study of the Effect of Daily Treatment with MPC-7869 in Subjects with Dementia of the Alzheimer’s Type | |||||||||||||
Medical condition: Treatment of Alzheimer’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) BE (Completed) DE (Prematurely Ended) NL (Ongoing) SE (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023852-10 | Sponsor Protocol Number: 18F-AV-45-020 | Start Date*: 2011-10-03 | |||||||||||
Sponsor Name:Avid Radiopharmaceuticals, Inc. | |||||||||||||
Full Title: 18F-AV-45 Amyloid PET Imaging in Primary Progressive Aphasia | |||||||||||||
Medical condition: Focal dementia syndromes - primary aphasia | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003705-42 | Sponsor Protocol Number: 15-09 | Start Date*: 2016-02-18 | ||||||||||||||||||||||||||
Sponsor Name:VU University Medical Center | ||||||||||||||||||||||||||||
Full Title: Longitudinal imaging of tau accumulation in the preclinical stages of AD | ||||||||||||||||||||||||||||
Medical condition: Alzheimer's Disease (AD), preclincal stages of AD | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004230-10 | Sponsor Protocol Number: 15-14 | Start Date*: 2016-11-16 | |||||||||||||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||||||||||||
Full Title: Validating in vivo quantification of tau with [18F]AV-1451 PET | |||||||||||||||||||||||
Medical condition: Alzheimer's Disease (AD) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-004675-35 | Sponsor Protocol Number: AAB-001-251 | Start Date*: 2007-08-20 | |||||||||||
Sponsor Name:Elan Regulatory Holdings Ltd | |||||||||||||
Full Title: A Phase II, Multicenter, Open-Label, Long-Term Treatment Study to Determine the Safety, Tolerability and Efficacy of AAB-001 (ELN115727) in Patients with Alzheimer's Disease who Participated in Stu... | |||||||||||||
Medical condition: Mild to Moderate Alzheimers Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003616-21 | Sponsor Protocol Number: MRZ 90001-0608/1 | Start Date*: 2007-09-07 | |||||||||||
Sponsor Name:Merz Pharmaceuticals GmbH | |||||||||||||
Full Title: Prospective, single-arm, multi-center, open-label study to investigate the efficacy and tolerability of the once daily [OD] memantine treatment | |||||||||||||
Medical condition: Dementia of Alzheimer’s Type [DAT] in patients with Mini Mental State Examination [MMSE] < 20 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001119-54 | Sponsor Protocol Number: H8A-MC-LZAX | Start Date*: 2013-09-27 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) versus Placebo | |||||||||||||
Medical condition: Mild Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) IT (Completed) SE (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000041-40 | Sponsor Protocol Number: P131 | Start Date*: 2022-02-22 |
Sponsor Name:Maastricht University | ||
Full Title: A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action | ||
Medical condition: Parkinson's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001187-52 | Sponsor Protocol Number: AX.- CL – 06a | Start Date*: 2004-11-12 | |||||||||||
Sponsor Name:Axonyx Corporation | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Two Different Dosages of Phenserine-tartrate in Patients with Mild to Moderate Probable Alzheimer’s Disea... | |||||||||||||
Medical condition: Alzheimer’s Disease is a chronic progressive illness leading to loss of cognitive and intellectual abilities such as memory function, judgement and abstract thinking. In addition to the cognitive d... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002855-25 | Sponsor Protocol Number: EIP-VX00-745-302 | Start Date*: 2015-03-11 | |||||||||||
Sponsor Name:EIP Pharma, LLC | |||||||||||||
Full Title: A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic ... | |||||||||||||
Medical condition: Alzheimer’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002527-17 | Sponsor Protocol Number: PBT2-201-EURO | Start Date*: 2006-09-20 | |||||||||||
Sponsor Name:Prana Biotechnology | |||||||||||||
Full Title: A 12-Week randomised, double-blind, placebo-controlled, parallel three-group study to assess the safety, tolerability and efficacy of two dose levels of PBT2 to slow progression of disease in patie... | |||||||||||||
Medical condition: Patients with early AD | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001724-19 | Sponsor Protocol Number: 2013/2 | Start Date*: 2014-05-13 | |||||||||||
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie | |||||||||||||
Full Title: Pilot study to assess P-glycoprotein function at the blood-brain barrier of patients with mild to moderate Alzheimer's disease | |||||||||||||
Medical condition: Alzheimer's disease and healthy controls (2 groups: 1 group with young healthy volunteers, 1 group with elderly healthy volunteers) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000170-29 | Sponsor Protocol Number: I9X-MC-MTAE | Start Date*: 2021-11-05 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer’s Disease | |||||||||||||
Medical condition: Alzheimer Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001315-40 | Sponsor Protocol Number: RF-2010-2319722 | Start Date*: 2014-12-03 | |||||||||||
Sponsor Name:IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli | |||||||||||||
Full Title: Amyloid Imaging in the “Italian Network for autosomal dominant Alzheimer’s disease and frontotemporal lobar degeneration (ItalianDIAfN)” | |||||||||||||
Medical condition: Autosomal Dominant Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003302-27 | Sponsor Protocol Number: ANAVEX2-73-AD-004 | Start Date*: 2020-01-22 | |||||||||||
Sponsor Name:Anavex Germany GmbH | |||||||||||||
Full Title: A Phase 2b/3, Double-Blind, Randomised, Placebo-Controlled 48 week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer’s Disease (AD). | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002102-31 | Sponsor Protocol Number: 221AD205 | Start Date*: 2019-03-20 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Blind, Controlled Study of Aducanumab (BIIB037) in Subjects With Mild Cognitive Impairment due to Alzheimer’s Disease or With Mild Alzheim... | |||||||||||||
Medical condition: Mild Cognitive Impairment due to Alzheimer's Disease and Mild Alzheimer's Dementia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) FR (Completed) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
